Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Genes Immun. 2011 Feb 10;12(5):378–389. doi: 10.1038/gene.2011.7

Figure 5. The ERK1/2 pathway inhibitor U0126 does not prevent c-jun transcript stabilization in MOLT-14 cells treated with APP.

Figure 5

MOLT-14 cells were treated with PBS or APP in cRPMI for two hours, followed by treatment with U0126 for two hours, and then with actinomycin D for the time indicated in the figure. RNA was extracted from each sample and subjected to quantitative RT-PCR for 18S and c-jun. Data represent mean of triplicate values +/−SD and are presented as the normalized amount of each transcript to 18S. The percentage of each transcript that remained following treatment was calculated after subtracting background (PBS t=90min). Data are representative of three independent experiments.